The anticancer effects of HDAC inhibitors require the immune system

Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFN...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Oncoimmunology Ročník 3; číslo 1; s. e27414
Hlavní autori: West, Alison C, Smyth, Mark J, Johnstone, Ricky W
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Taylor & Francis 01.01.2014
Landes Bioscience
Predmet:
anticancer immunity
anticancer therapy
Author's View
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
anticancer immunity
anticancer therapy
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
ISSN:2162-402X, 2162-4011, 2162-402X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
AbstractList Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
Author West, Alison C
Smyth, Mark J
Johnstone, Ricky W
Author_xml – sequence: 1
  givenname: Alison C
  surname: West
  fullname: West, Alison C
– sequence: 2
  givenname: Mark J
  surname: Smyth
  fullname: Smyth, Mark J
– sequence: 3
  givenname: Ricky W
  surname: Johnstone
  fullname: Johnstone, Ricky W
  email: ricky.johnstone@petermac.org
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24701376$$D View this record in MEDLINE/PubMed
BookMark eNptkU1LxDAQhoMofqxe_AHSowi7JmmTbC6CrJ8geFHwFtJ04kbaRJNU2X9v11VRcS4ZyPO-M8y7g9Z98IDQPsGTinByHLxxEyoqUq2hbUo4HVeYPqz_6LfQXkpPeCiOGS_lJtqilcCkFHwbze7mUGifndHeQCzAWjA5FcEWV2ens8L5uatdDjEVEV56F6HIg8J1Xe-hSIuUodtFG1a3CfY-3xG6vzi_m12Nb24vr2enN2NTSZzHHGTNreCY11zaeloxwaiRDTXGMilE2Yh6irlmGpeYVLwxDJdAG61tTaRl5QidrHyf-7qDxoDPUbfqObpOx4UK2qnfP97N1WN4VaXklGExGBx-GsTw0kPKqnPJQNtqD6FPikwpZ1Mph9uM0MHPWd9Dvi43AEcrwMSQUgT7jRCslsmoZTLqI5kBxn9g47LOLiz3dO3_EraSOG9D7PRbiG2jsl60Ido4hOWSKv_RvQONqaQV
CitedBy_id crossref_primary_10_1186_s13058_018_1068_x
crossref_primary_10_2174_0929867324666170801102124
crossref_primary_10_1667_RADE_20_00013
crossref_primary_10_3389_fimmu_2015_00029
crossref_primary_10_1158_2326_6066_CIR_18_0875
crossref_primary_10_1186_s13046_021_01909_7
crossref_primary_10_1517_13543784_2016_1146251
crossref_primary_10_3390_biomedicines10112767
crossref_primary_10_1038_s41598_021_80999_x
crossref_primary_10_3892_or_2016_5008
crossref_primary_10_1158_2159_8290_CD_20_1145
crossref_primary_10_1016_S1470_2045_15_70056_2
crossref_primary_10_1016_j_apsb_2023_09_015
crossref_primary_10_3892_or_2017_5773
crossref_primary_10_1016_j_bcp_2019_113698
crossref_primary_10_4049_jimmunol_2300475
crossref_primary_10_1002_1878_0261_12953
crossref_primary_10_2217_imt_2016_0014
crossref_primary_10_3389_fimmu_2022_865975
crossref_primary_10_1016_j_ijbiomac_2024_133883
crossref_primary_10_2217_fon_14_205
crossref_primary_10_3390_ijms18050945
crossref_primary_10_2174_0929867325666181106114421
crossref_primary_10_1053_j_seminoncol_2015_05_009
crossref_primary_10_1016_j_addr_2017_06_010
crossref_primary_10_1186_s40425_019_0518_z
crossref_primary_10_1016_j_ejmech_2022_114920
crossref_primary_10_1016_j_jid_2020_08_023
crossref_primary_10_3389_fphar_2018_00792
crossref_primary_10_3389_fimmu_2022_809761
crossref_primary_10_3390_ijms19123952
crossref_primary_10_4161_onci_29179
crossref_primary_10_3389_fimmu_2018_00512
crossref_primary_10_1016_j_omto_2020_08_003
crossref_primary_10_1038_nrc_2017_17
crossref_primary_10_1186_s13148_024_01698_8
crossref_primary_10_1002_jcp_25604
crossref_primary_10_3390_vaccines4040043
crossref_primary_10_2217_epi_14_91
crossref_primary_10_1038_nrd_2016_256
crossref_primary_10_1186_s12885_021_08702_x
crossref_primary_10_12998_wjcc_v9_i26_7643
crossref_primary_10_3389_fimmu_2020_01469
crossref_primary_10_1158_2326_6066_CIR_17_0080
crossref_primary_10_14712_fb2018064040125
crossref_primary_10_1053_j_seminoncol_2018_05_004
crossref_primary_10_1158_2159_8290_CD_16_1020
crossref_primary_10_1371_journal_pgen_1010376
crossref_primary_10_1080_2162402X_2017_1392426
crossref_primary_10_1016_j_bbcan_2021_188585
crossref_primary_10_1002_cbf_3463
crossref_primary_10_1124_jpet_115_229328
crossref_primary_10_1517_17425247_2015_1021678
Cites_doi 10.4049/jimmunol.165.12.7017
10.1200/JCO.2010.28.9066
10.1200/JCO.2006.10.2434
10.1158/0008-5472.CAN-05-0599
10.1158/0008-5472.CAN-13-0890
10.1073/pnas.052702999
10.1073/pnas.051507098
10.1073/pnas.1011037108
10.1186/1479-5876-5-64
10.1038/nm1652
ContentType Journal Article
Copyright Copyright © 2014 Landes Bioscience 2014
Copyright_xml – notice: Copyright © 2014 Landes Bioscience 2014
DBID 0YH
AAYXX
CITATION
NPM
7X8
5PM
DOI 10.4161/onci.27414
DatabaseName Taylor & Francis Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2162-402X
ExternalDocumentID PMC3962507
24701376
10_4161_onci_27414
10927414
Genre Other
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 00X
0YH
53G
AAKDD
ABUPF
ACGFS
ADBBV
ADCVX
AENEX
AIJEM
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQTUD
BABNJ
BLEHA
CCCUG
DEAQA
DGEBU
DGFLZ
EBS
EJD
EMOBN
EUPTU
GROUPED_DOAJ
H13
HYE
KRBQP
KSSTO
KTTOD
KWAYT
KYCEM
M4Z
O9-
OK1
OVD
RPM
TDBHL
TEORI
TFL
TFW
TNTFI
TTHFI
4.4
AAYXX
CITATION
LJTGL
ABDBF
ACUHS
EBD
NPM
7X8
5PM
ID FETCH-LOGICAL-c490t-6e9b6f7606b69fb845752c9d2ccf59773d7b806a5a030146dc503e2daafb19f53
IEDL.DBID 0YH
ISICitedReferencesCount 70
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000339952700024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2162-402X
2162-4011
IngestDate Tue Nov 04 01:36:30 EST 2025
Sun Nov 09 13:34:12 EST 2025
Thu Apr 03 06:57:51 EDT 2025
Tue Nov 18 22:30:18 EST 2025
Sat Nov 29 03:25:28 EST 2025
Mon Oct 20 23:43:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords anticancer immunity
anticancer therapy
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
Language English
License open-access: http://creativecommons.org/licenses/by-nc/3.0/: This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c490t-6e9b6f7606b69fb845752c9d2ccf59773d7b806a5a030146dc503e2daafb19f53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
OpenAccessLink https://www.tandfonline.com/doi/abs/10.4161/onci.27414
PMID 24701376
PQID 1826589901
PQPubID 23479
ParticipantIDs informaworld_taylorfrancis_310_4161_onci_27414
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3962507
crossref_primary_10_4161_onci_27414
proquest_miscellaneous_1826589901
crossref_citationtrail_10_4161_onci_27414
pubmed_primary_24701376
PublicationCentury 2000
PublicationDate 1/1/2014
2014-01-00
2014-Jan-01
20140101
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – month: 01
  year: 2014
  text: 1/1/2014
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncoimmunology
PublicationTitleAlternate Oncoimmunology
PublicationYear 2014
Publisher Taylor & Francis
Landes Bioscience
Publisher_xml – name: Taylor & Francis
– name: Landes Bioscience
References R2
R10
R3
R4
R5
R6
R7
R8
R9
R1
References_xml – ident: R4
  doi: 10.4049/jimmunol.165.12.7017
– ident: R2
  doi: 10.1200/JCO.2010.28.9066
– ident: R1
  doi: 10.1200/JCO.2006.10.2434
– ident: R5
  doi: 10.1158/0008-5472.CAN-05-0599
– ident: R7
  doi: 10.1158/0008-5472.CAN-13-0890
– ident: R8
  doi: 10.1073/pnas.052702999
– ident: R10
  doi: 10.1073/pnas.051507098
– ident: R6
  doi: 10.1073/pnas.1011037108
– ident: R3
  doi: 10.1186/1479-5876-5-64
– ident: R9
  doi: 10.1038/nm1652
SSID ssj0000605639
Score 2.2855763
Snippet Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis...
SourceID pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e27414
SubjectTerms anticancer immunity
anticancer therapy
Author's View
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
Title The anticancer effects of HDAC inhibitors require the immune system
URI https://www.tandfonline.com/doi/abs/10.4161/onci.27414
https://www.ncbi.nlm.nih.gov/pubmed/24701376
https://www.proquest.com/docview/1826589901
https://pubmed.ncbi.nlm.nih.gov/PMC3962507
Volume 3
WOSCitedRecordID wos000339952700024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAWR
  databaseName: Taylor & Francis Journals
  customDbUrl:
  eissn: 2162-402X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000605639
  issn: 2162-402X
  databaseCode: TFW
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwED7xlFh4P8pLRrAwBNLEceIRFapOiAFEmSLbsUUklKK2IPHvuYvbqq26wOIlZ8W6O9v32efvAK4MNyoxSgdprKOAN5sK10Etg9g5gx7Em04VdbGJ9PEx63bl0xKI8VsYSqskDO08UUS9VtPkVrquQELh-G2vMuUN0a7wZViNEI8Q6ArfOpOzlRBjdNx5PRvpXJeZ_WeGnXRRjDmfKjm197S3_jvqbdgcRZvszrvHDizZahfWff3Jnz1ooZMwVC0thcb22Si5g_Uc69zftVhZvZe6pHo8rG8pZdgyjBdZSW9KLPMk0Pvw0n54bnWCUVWFwHAZDgNhpRYuReCihXQ64xiwRUYWkTGOyOjiItVZKFSiarglCpOEsY0KpZxuSpfEB7BS9Sp7BEwJaWQWC2Gk467gEuVM4rR2mic2CRtwPdZ1bkaU41T54iNH6EFKyUkpea2UBlxOZD890cZCqZtpk-XD-ljD-Rokebyow8XYqDlOHLoNUZXtfQ1yAlZJRteCDTj0Rp78OOIpUTGKBqQz5p8IECn37JeqfK_JuWOJiDJMj_860BPYwFiM-9OdU1gZ9r_sGayZ72E56J_X_o1t2s2wfW6__gJJnwVq
linkProvider Taylor & Francis
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbWrsV22dbHuuzRaWgvPbhzbEm2jkG2IMWyYIcM602QZAkxMDiFkxTov59ouUES5NKdTcMCSYkfKfojwKWhRjGjdJSlOolot6v8OahFlDpnvAfRrlNFM2wiG4_z21vxqy1dzNu2SsyhXSCKaM5q3NxYjMYdjnj866wy5TXyrtA9eM58gEXS_Mngz6q4EnuQ7kNvoCPdemUjAG3Qk-4Cmdu9kmvBZ_D6v5f9Bl61eJP0goMcwTNbHcNhmED5cAJ97ybEKxcPQ2Nr0rZ3kJkjw2-9PimraalLnMhDaotNw5Z4xEhK_KvEkkADfQq_B98n_WHUzlWIDBXxIuJWaO4yn7poLpzOqYdsiRFFYoxDOrq0yHQec8VUk3DxwrA4tUmhlNNd4Vj6FvarWWXfAVFcGJGnnBvhqCuo8HKGOa2dpsyyuANXj8qWpiUdx9kXf6VPPlApEpUiG6V04GIlexeoNnZKXa_bTC6awoYLU0hkuuuFL49WlX7r4H2IquxsOZeYWrEcLwY7cBasvPpwQjMkY-QdyDbsvxJAWu7NJ1U5bei5U-Fzyjh7_9SFfoYXw8nPkRzdjH98gJcemdFQ6_kI-4t6aT_BgblflPP6vHH2f9MzB5o
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB2xiwv7UlYjuHAIpInjxEdUqIpAVQ8guFm2Y4tIKK3agsTf44nbiqJe4JyxYs1iv7HHbwAuNNUy0VIFaayigNbr0q2Digextdp5EK1bmVfNJtJ2O3t95Z05YOO3MFhWiTm09UQR1VqNwd3LLQY4wvHrbqmLK6RdofOw6PAyQ89-ar5MzlZCh9HdzuvZSH8Nmdp_pthJZ2HM36WSP_ae5vp_Z70BayO0SW68e2zCnCm3YNn3n_zahoZzEuJUi0uhNn0yKu4gXUtatzcNUpRvhSqwHw_pGywZNsThRVLgmxJDPAn0Djw3754arWDUVSHQlIfDgBmumE1d4qIYtyqjDrBFmueR1hbJ6OI8VVnIZCKrdIvlOgljE-VSWlXnNol3YaHslmYfiGRc8yxmTHNLbU65k9OJVcoqmpgkrMHlWNdCjyjHsfPFu3CpBypFoFJEpZQanE9ke55oY6bU1U-TiWF1rGF9DxIRzxpwNjaqcIGDtyGyNN2PgcDEKsnwWrAGe97Ikx9HNEUqRlaDdMr8EwEk5Z7-UhZvFTl3zF1GGaYHf53oKax0bpvi8b79cAirDpZRf9BzBAvD_oc5hiX9OSwG_ZPK1b8B07oGTA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+anticancer+effects+of+HDAC+inhibitors+require+the+immune+system&rft.jtitle=Oncoimmunology&rft.au=West%2C+Alison+C&rft.au=Smyth%2C+Mark+J&rft.au=Johnstone%2C+Ricky+W&rft.date=2014-01-01&rft.pub=Taylor+%26+Francis&rft.eissn=2162-402X&rft.volume=3&rft.issue=1&rft_id=info:doi/10.4161%2Fonci.27414&rft.externalDBID=0YH&rft.externalDocID=10927414
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon